Most skin cancer drugs that activate the immune system work by triggering immune cells, called T-cells, to attack tumors, but when T-cells are activated for too long, they can wear out and cease to function.
In a new study led by Penn State College of Medicine, scientists found that another type of immune cell — natural killer cells — can be harnessed to pick up the slack when T-cells no longer work.
